Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.66 USD | +9.21% | +8.50% | +88.64% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 208M |
---|---|---|---|---|---|
Net income 2024 * | -35M | Net income 2025 * | -39M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-6.09
x | P/E ratio 2025 * |
-5.72
x | Employees | 12 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.9% |
Latest transcript on Atossa Therapeutics, Inc.
1 day | +9.21% | ||
1 week | +8.50% | ||
Current month | +9.93% | ||
1 month | -20.95% | ||
3 months | +94.61% | ||
6 months | +137.14% | ||
Current year | +88.64% |
Managers | Title | Age | Since |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 08-11-30 |
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Heather Rees
DFI | Director of Finance/CFO | - | 16-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 08-11-30 |
Director/Board Member | 66 | 14-02-28 | |
H. Remmel
BRD | Director/Board Member | 72 | 12-01-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 1.66 | +9.21% | 1,360,532 |
24-05-02 | 1.52 | -0.65% | 1,218,175 |
24-05-01 | 1.53 | +1.32% | 967,983 |
24-04-30 | 1.51 | -1.31% | 1,451,633 |
24-04-29 | 1.53 | 0.00% | 1,047,842 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+88.64% | 208M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ATOS Stock